Large Comparative Trials Deserve More Support, FDAer Says
Executive Summary
Thrombolytic agent mortality studies demonstrate the value of large head-to-head trials to detect small outcomes differences between drugs, Center for Drug Evaluation & Research Acting Deputy Director Mark Goldberger said
You may also be interested in...
AHRQ Comparative Research Agenda Will Start With Rx Drugs
The Agency for Healthcare Research & Quality is recommending that its initial list of priorities for comparative effectiveness research should focus on prescription drugs
Genentech TNKase/ReoPro Study Looking At New Use For Activase Successor
FDA wants Genentech to move promptly to update labeling for its Activase-successor product TNKase once data from ongoing combination therapy trials are available.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011